Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses

被引:79
作者
Diwan, M
Elamanchili, P
Lane, H
Gainer, A
Samuel, J [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Dent Pharm Ctr 3118, Edmonton, AB T6G 2N8, Canada
[2] Univ Alberta, Surg Med Res Inst, Dent Pharm Ctr 1074, Edmonton, AB, Canada
关键词
CD34 stem cells; antigen delivery; in vitro immunization; primary immune response; MPLA; CpG ODN;
D O I
10.1080/10611860410001670026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dendritic cells (DCs) in the peripheral tissues act as sentinels of the immune system. They detect and capture pathogens entering the body and present their antigens to T cells to trigger responses directed towards elimination of the pathogen. The induction of peripheral tolerance against self and certain foreign antigens is also believed to be mediated through DCs. The outcome of any immune response is largely controlled by the microenvironment of antigen capture, processing and presentation by DCs. The "context" of antigen delivery to DCs will directly influence the microenvironment of antigen presentation and hence the regulation of immune responses. We report here preliminary investigations describing the formulation of a pharmaceutically acceptable, biodegradable, and strategic nanoparticulate delivery system, and its application for efficient antigen loading of DCs to achieve antigen specific T cell activation. "Pathogen-mimicking" nanoparticles capable of interacting with DCs were fabricated by incorporating monophosphoryl lipid A (MPLA; toll-like receptor (TLR) 4 ligand) or CpG ODN (seq #2006; TLR9 ligand) in biodegradable copolymer, poly( d , l -lactic-co-glycolic acid) (PLGA). The uptake of PLGA nanoparticles by human umbilical cord blood derived DCs (DCs propagated from CD34(+) progenitors) was conclusively demonstrated by scanning electron microscopy (SEM), fluorescence activated cell sorting (FACS) and confocal laser scanning microscopy (CLSM). Cell phenotype at day 12 of cultures was determined as immature DC using specific cell surface markers, i.e. CD11c(hi) (similar to90%), MHC-II+ (similar to70%), CD86(low) (similar to20%), CD83(low) (similar to5%), CD80(+) (similar to40%), CD40(+) (similar to40%), and CCR7(low) (similar to5%). Tetanus toxoid (TT), a model antigen, was encapsulated in nanoparticles along with an immunomodulator, i.e. either MPLA or CpG ODN. DCs pulsed with various antigen formulations were co-cultured with autologous naive T cells at various cell ratios (DC: T cells were 1:5-20). The DCs pulsed with TT and MPLA together in nanoparticles induced significantly higher T cell proliferation (P <0.05) as compared to when DCs pulsed with TT and MPLA in solution were employed. A similar trend was observed when CpG ODN was used instead of MPLA in the TT nanoparticles. This strategy of antigen delivery to DCs was then tested with a cancer vaccine candidate, a MUC1 lipopeptide. The T cell proliferation observed in the presence of nanoparticulate MUC1 and MPLA pulsed-DCs was much higher than DCs pulsed with soluble antigen (P <0.0005). These results indicate that PLGA nanoparticles mimicking certain features of pathogens are efficient delivery systems for targeting vaccine antigens to DCs and activation of potent T cell responses.
引用
收藏
页码:495 / 507
页数:13
相关论文
共 79 条
[1]   Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2 [J].
Agrawal, B ;
Krantz, MJ ;
Reddish, MA ;
Longenecker, BM .
NATURE MEDICINE, 1998, 4 (01) :43-49
[2]   The biological role of mucins in cellular interactions and immune regulation: prospects for cancer immunotherapy [J].
Agrawal, B ;
Gendler, SJ ;
Longenecker, BM .
MOLECULAR MEDICINE TODAY, 1998, 4 (09) :397-403
[3]  
Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO
[4]  
2-U
[5]   Do CD4+CD25+ immunoregulatory T cells hinder tumor immunotherapy? [J].
Antony, PA ;
Restifo, NP .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (03) :202-206
[6]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[7]   T cells induce extended class II MHC compartments in dendritic cells in a toll-like receptor-dependent manner [J].
Boes, M ;
Bertho, N ;
Cerny, J ;
den Brouw, MO ;
Kirchhausen, T ;
Ploegh, H .
JOURNAL OF IMMUNOLOGY, 2003, 171 (08) :4081-4088
[8]   Dendritic cells can be successfully generated from CD34+ cord blood cells in the presence of autologous cord blood plasma [J].
Borràs, FE ;
Matthews, NC ;
Patel, R ;
Navarrete, C .
BONE MARROW TRANSPLANTATION, 2000, 26 (04) :371-376
[9]   Dendritic cells in cancer vaccines [J].
Brossart, P ;
Wirths, S ;
Brugger, W ;
Kanz, L .
EXPERIMENTAL HEMATOLOGY, 2001, 29 (11) :1247-1255
[10]   Assuring Quality and Performance of Sustained and Controlled Release Parenterals: AAPS Workshop Report, Co-Sponsored by FDA and USP [J].
Diane J. Burgess ;
Ajaz S. Hussain ;
Thomas S. Ingallinera ;
Mei-Ling Chen .
Pharmaceutical Research, 2002, 19 (11) :1761-1768